Pharmaceutical firms turn away quasi-drugs

Published: 2003-02-06 06:59:00

Updated: 2003-02-06 06:59:00

Pharmaceutical business sources say that more clear definition on quasi-drugs, swifted from some OTCs whose safety and efficacy was already established, should be required to promote the sagging production of pharmaceutical firms on these products.

Currently, pharmacies are selling any items ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK